As of the time of publication, the stock has risen more than 12%, reaching $9.355.
According to the Zhixun Finance APP, on Friday, novavax (NVAX.US) saw its stock price rise, with the stock surging more than 12% to $9.355 as of the time of publication. In terms of news, novavax will sell its production facility in the Czech Republic for $0.2 billion to novo-nordisk a/s (NVO.US). According to a statement released on Wednesday, novavax will transfer to novo-nordisk a 0.15 million square foot recombinant protein manufacturing facility and supporting structures, existing workforce, and all relevant and necessary infrastructure. In addition to a $0.19 billion cash payment in 2024 and an additional $10 million in 2025, novavax expects the sale of the facility to reduce annual operating costs by approximately $80 million. Novavax President and CEO John C. Jacobs said: "The decision to sell the manufacturing facility in the Czech Republic aligns with our previously announced commitment to develop novavax into a more streamlined and agile organization, focusing on our pipeline assets and technology platform."
